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While multiple a 1–2-mannosidases are necessary for glycoprotein N-glycan
maturation in vertebrates, a single bacterial a1–2-mannosidase can be sufficient
to cleave all a1–2-linked mannose residues in host glycoprotein N-glycans. We
report here the characterization and crystal structure of a new a1–2-mannosi-
dase (EfMan-I) from Enterococcus faecalis, a Gram-positive opportunistic
human pathogen. EfMan-I catalyzes the cleavage of a1–2-mannose from not
only oligomannoses but also high-mannose-type N-glycans on glycoproteins. Its
2.15 "A resolution crystal structure reveals a two-domain enzyme fold similar to
other CAZy GH92 mannosidases. An unexpected potassium ion was observed
bridging two domains near the active site. These findings support EfMan-I as
an effective catalyst for in vitro N-glycan modification of glycoproteins with
high-mannose-type N-glycans 4.
Keywords: alpha-mannosidase; crystal structure; glycoprotein modification;
mannosidase; N-glycan enzymatic modification
N-Linked glycan modification is an important post-
translational modification (PTM) of proteins that
affects their conformation, solubility, stability, immuno-
genicity, and recognition by other molecules [1,2]. In
fact, many therapeutic proteins are N-glycosylated gly-
coproteins and proper glycosylation is important for
their pharmacokinetics, cellular distributions, and bio-
logical activities [3–5]. Glycan engineering of therapeu-
tic glycoproteins has shown to improve their functions
[6–8]. Among various methods [9–11] including glyco-
engineering of host biosynthetic pathways [12–14],
chemoselective ligation of tagged proteins and glycans
[10,11], total chemical synthesis by native chemical liga-
tion [15], in vitro chemoenzymatic glycosylation remod-
eling [16], and in vitro enzymatic glycosylation of
glycoproteins [8], the latter is an attractive strategy to
produce glycan-defined glycoproteins [8].
In eukaryotes, N-glycosylation is a part of a glyco-
protein quality control process in the endoplasmic
reticulum (ER). Eukaryotic N-glycans usually belong
to one of the three types of structures including oligo-
mannose, complex, and hybrid. These structures share
a common tri-mannose core Man a1–3(Mana1–6)
Manb1–4GlcNAcb1–4GlcNAcb1–(Asn-X-Ser/Thr) but
differ on the extension at the non-reducing end [17],
with or without an additional core fucose [18], and the
linkage of the core fucose [19]. Oligomannose-type (or
high-mannose type) N-glycans can be considered as
precursors for the biosynthesis of complex and
hybrid-type N-glycans in glycoproteins. Early steps of
such conversion involve trimming high-mannose
N-glycans by a1–2-mannosidase-catalyzed reactions.
In human, multiple a1–2-mannosidases, including
ER a1–2-mannosidase I (ERManI) and three Golgi
Abbreviations
2-AB, 2-aminobenzamide; EfMan-I, efficient a1–2-mannosidase; EfMan-I, Enterococcus faecalis a1–2-mannosidase; ER, endoplasmic reticu-
lum; HAIs, health care-associated infections; HPLC, high-performance liquid chromatography; IPTG, isopropyl-1-thio-D-galactopyranoside; MS,
mass spectrometry; PTM, post-translational modification; SSRL, Stanford Synchrotron Radiation Lightsource.
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a1–2-mannosidases (GM1A, GM1B, and GMIC), are
responsible for removing four a1–2-linked mannose
from high-mannose-type N-glycan Man9GlcNAc2 to
form Man5GlcNAc2 [20]. In comparison, a1–2-man-
nosidases capable of catalyzing the cleavage of all four
a1–2-mannose residues in high-mannose type N-glycan
Man9GlcNAc2 have been identified in a limited num-
ber of bacteria such as Bacteroides thetaiotaomicron
VPI-5482 (Bt3990 and Bt2199) [21], Streptococ-
cus pneumoniae (SpGH92) [22], and Cellulosimicro-
bium cellulans [23]. An exo-1,2-a-D-mannanase purified
from Bacillus sp. M-90 has also been shown to cat-
alyze the cleavage of all a1–2-linked mannose residues
in Man9GlcNAc2 to form Man5GlcNAc2 [24]. All
known exo-a1–2-mannosidases are mainly classified
into three glycoside hydrolase (GH) families in the
Carbohydrate Active Enzyme (CAZy) database (http://
www.cazy.org) [25–27] including GH38, GH47, and
GH92. While characterized mammalian ER and Golgi
a1–2-mannosidases are in the CAZy GH47 family [20],
most bacterial a1–2-mannosidases characterized so far
are in the GH92 family, and lysosomal a-mannosi-
dases are in the GH38 family.
Bacterial a1–2-mannosidases are attractive enzymes
for in vitro enzymatic glycan modification of the high-
mannose-type N-glycans in natural and recombinant
glycoproteins to hybrid or complex-type N-glycans.
They are also appealing targets for better understand-
ing how host glycoprotein glycans can be utilized by
commensals and pathogenic bacteria to shape micro-
biota community [28]. By sequence alignment and lit-
erature survey, we identified EF2217 from
Enterococcus faecalis V583 [29], a member in the
CAZy GH92 family, as a promising candidate for a
novel and highly active bacterial a1–2-mannosidase.
E. faecalis is a Gram-positive commensal bacterium
and an opportunistic pathogen that can cause health
care-associated infections (HAIs) including urinary
tract infections, bacteremia, and infective endocarditis
[30]. It was the first clinical vancomycin-resistant ente-
rococcal isolate reported in the USA [31], and the full
genomic DNA of strain V583 was reported in 2003
[29]. More importantly, the bacterium was shown to
be able to use high-mannose-type N-glycans efficiently
but not sialylated N-linked glycans for growth [32].
Two endo-b-N-acetylglucosaminidases from E. faecalis
V583 (EF0114 and EF2683) were isolated and found
to be able to cleave high-mannose N-glycan from gly-
coprotein to form a single N-linked N-acetylglu-
cosamine (GlcNAc) residue [32–34]. Activities of
exo-mannosidases in producing free mannose residues
from the N-glycans released from glycoproteins were
also observed [32] but not characterized. We describe
here that EF2217 is an efficient a1–2-mannosidase
(EfMan-I) catalyzing the cleavage of a1–2-linked man-
nose residues from not only synthetic mannosides and
high-mannose N-glycans released from glycoproteins,
but also high-mannose N-glycans on glycoproteins.
The enzyme is thus an effective catalyst and a very
useful tool for in vitro enzymatic modification of gly-
coproteins with high-mannose-type N-glycans. The
crystal structure reveals that it shares high similarity
with other bacterial GH92 a-mannosidases, with an
N-terminal b-sandwich domain and a C-terminal a-he-
lical domain. The active site lies in a cleft between the
two domains and contains a catalytic calcium ion. An
unexpected potassium ion was also observed bridging
the two domains near the active site that may help
position the two domains.
Materials and methods
Bacterial strains, plasmids, and materials
Escherichia coli electrocompetent DH5a and chemically
competent BL21 (DE3) cells were purchased from Invitro-
gen (Carlsbad, CA, USA). Genomic DNA of E. faecalis
V583 (ATCC#700802D-5) was from American Type Cul-
ture Collection (ATCC, Manassas, VA, USA). Vector plas-
mid pET22b(+) was from Novagen (EMD Biosciences Inc.
Madison, WI, USA). Restriction enzymes NdeI and XhoI
were purchased from New England Biolabs, Inc. (Beverly,
MA, USA). Nickel-nitrilotriacetic acid agarose (Ni2+-NTA
agarose) was from Qiagen (Valencia, CA, USA). GeneJET
Plasmid Miniprep kit and GeneJET PCR Purification kit
were from Thermo Scientific (San Diego, CA, USA). Her-
culase-enhanced DNA polymerase was from Stratagene (La
Jolla, CA, USA). T4 DNA ligase and 1 kb DNA ladder
were from Promega (Madison, WI, USA). para-Nitro-
phenyl-a-D-mannopyranoside (ManapNP) was from Chem-
Impex Int’L Inc. (Wood Dale, IL, USA). a2-Mannobiose,
a3-mannobiose, and 3a,6a -mannopentaose (Man5) were
from Santa Cruz Biotechnology (Dallas, TX, USA). a6-
Mannobiose, hexokinase from S. cerevisiae, phosphoglu-
cose isomerase from baker’s yeast, and glucose-6-phosphate
dehydrogenase from L. mesenteroides were 5from Sigma-
Aldrich (Saint Louis, MO, USA). 1,3-a-1,6-a-D-Man-
notriose (Man3) was purchased from Carbosynth Limited
(San Diego, CA, USA). E. coli phosphomannose isomerase
was from Megazyme (Chicago, IL, USA).
Cloning of EfMan-I
Efficient a1–2-mannosidase was cloned as a C-His6-tagged
fusion protein in pET22b(+) vector using genomic DNA of
E. faecalis V583 (ATCC#700802D-5) as the template for
PCRs. The primers used were as follows: forward primer
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50-GATCCATATGAATATTCAAGCGATTGATACGCG-
30 (NdeI restriction site is italicized) and reverse primer
50-ACGCCTCGAG TTTTTCCGTACTTAATGAAAACGG-
30 (XhoI restriction site is italicized). PCR was performed in a
50-µL reaction mixture containing genomic DNA (1 µg), for-
ward and reverse primers (1 µM each), 109 Herculase buffer
(5 µL), dNTP mixture (1 mM), and 5 U (1 µL) of Herculase-
enhanced DNA polymerase. The reaction mixture was sub-
jected to 30 cycles of amplification with an annealing tempera-
ture of 52 °C. The resulting PCR product was purified and
digested with NdeI and XhoI restriction enzymes. The purified
and digested PCR product was ligated with predigested
pET22b(+) vector and transformed into electrocompetent
E. coli DH5a cells. Selected clones were grown for minipreps
and characterization by restriction mapping and DNA
sequencing performed by Davis Sequencing Facility at the
University of California, Davis.
Expression and purification of EfMan-I
Escherichia coli strains were cultured in LB rich medium
(10 g!L"1 tryptone, 5 g!L"1 yeast extract, and 10 g!L"1
NaCl) supplemented with ampicillin (100 µg!mL"1). Overex-
pression of EfMan-I was achieved by inducing the E coli
BL21 (DE3) cell culture with 0.15 mM of isopropyl-1-thio-D-
galactopyranoside (IPTG) when the OD600 nm of the culture
reached 0.8–1.0 followed by incubation at 20 °C for 20 h.
Bacterial cells were harvested by centrifugation at 4 °C
in a Sorvall Legend RT centrifuge with a hanging bucket
rotor at 4000 r.p.m6 . for 2 h. Harvested cells were resus-
pended in lysis buffer (Tris/HCl buffer, 100 mM, pH 8.0
containing 0.1% Triton X-100) (20 mL for cells collected
from 1 L cell culture). Lysozyme (100 µg!mL"1) and
DNase I (5 µg!mL"1) were added to the cell resuspension.
The resulting mixture was incubated at 37 °C for 1 h with
shaking at 200 r.p.m. Cell lysate (supernatant) was
obtained by centrifugation at 12 000 r.p.m.7 for 15 min.
Purification was carried out by loading the supernatant
onto a Ni2+-NTA column pre-equilibrated with 10 column
volumes of binding buffer (5 mM imidazole, 0.5 M NaCl,
50 mM Tris/HCl, pH 7.5). The column was washed with 10
column volumes of binding buffer and 10 column volumes
of washing buffer (24 mM imidazole, 0.5 M NaCl, 50 mM
Tris/HCl, pH 7.5). The target protein was eluted with Tris/
HCl buffer (50 mM, pH 7.5) containing imidazole (200 mM)
and NaCl (0.5 M). The fractions containing the purified
enzymes were collected, dialyzed against Tris/HCl buffer
(20 mM, pH 7.5) containing 10% glycerol with changing of
dialysis buffer for three times, and stored at 4 °C.
Substrate specificity studies of EfMan-I
Typical enzymatic assays were performed in a 10-µL reac-
tion mixture in MES buffer (100 mM, pH 6.0) containing
substrate (10 mM) and EfMan-I (1.0 or 10 µg). Substrates
used were as follows: Man apNP, a2-mannobiose, a3-man-
nobiose, a6-mannobiose, Man3, and Man5. Reactions were
allowed to proceed for 30 min, 18 h, or 24 h at room tem-
perature (RM) or at 37 °C and were analyzed by TLC in a
developing solvent (n-PrOH : H2O : NH4OH = 5 : 2 : 1 or
n-PrOH : H2O: NH4OH = 3 : 2 : 1).
pH profile of EfMan-I
Standard enzymatic assays were carried out in duplicate in
384-well plates in a final volume of 20 µL in a buffer
(100 mM) with a pH ranging from 3.0 to 9.0 containing Man-
apNP (0.3 mM), CaCl2 (4 mM), and EfMan-I (10.0 µg). Buf-
fers used were as follows: citric acid-Na2HPO4, pH 3.0–4.0;
NaOAc/HOAc, pH 4.5; MES, pH 5.0–6.5, and Tris/HCl pH
7.0–9.0. Reactions were incubated at 37 °C for 30 min and
quenched by adding 40 µL of N-cyclohexyl-3-amino-
propanesulfonic acid (CAPS) buffer (0.5 M, pH 10.5).
The amounts of para-nitrophenolate formed were deter-
mined by measuring the A405 nm of the reaction mixtures
using a microplate reader. Reactions of GalbpNP with
an excess amount of b-galactosidase were used as con-
trols.
Effects of ethylenediaminetetraacetic acid (EDTA)
and metal Ions on EfMan-I
Ethylenediaminetetraacetic acid (10 mM), CaCl2, or MgCl2
were added at different concentrations (1, 2, 4, 8, 10,
20 mM) to reactions in MES buffer (100 mM, pH 6.0) to
analyze their effects on the mannosidase activity of EfMan-
I (10.0 µg) against ManapNP. Reactions without the addi-
tion of EDTA or metal ions were used as a control. The
concentrations of the substrates and other reaction condi-
tions were the same as described above for the pH profile
assays.
Kinetic studies of EfMan-I
Kinetic assays were carried out using three different sub-
strates including ManapNP, a2-mannobiose, and RNaseB.
When ManapNP was used as the substrate, the assays were
carried out in duplicates in 384-well plates in a total vol-
ume of 20 µL in MES buffer (100 mM, pH 6.0) containing
CaCl2 (4 mM), ManapNP at different concentrations in the
range of 0.1–10 mM (0.1, 0.2, 0.4, 0.5, 1, 2, 5, 10 mM), and
EfMan-I (14 µg). Reactions were incubated at 37 °C for
10 min and quenched by adding 40 µL of CAPS buffer
(0.5 M, pH 10.5). The amounts of para-nitrophenolate
formed were analyzed by a microplate reader and
compared to a pNP standard curve. Apparent kinetic
parameters were obtained by fitting the averages to the
Michaelis–Menten equation using Grafit 5.0.
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When a2-mannobiose was used as the substrate, reactions
were performed in duplicate at 37 °C for 10 min in a total
volume of 50 µL in MES buffer (100 mM, pH 6.0) containing
varied concentrations of a2-mannobiose (0.1, 0.2, 0.5, 1, 2, 5,
and 10 mM) and EfMan-I (6.2 nM). Reactions were quenched
by incubating the reaction mixtures at 98 °C for 10 min. Pre-
cipitates were removed by centrifugation (11 000 g, 5 min,
4 °C). The concentrations of mannose released were deter-
mined by a coupled enzyme assay as described [21]. Briefly,
reactions were carried out at 25 °C in duplicate in a 384-well
plate in the presence of Tris/HCl buffer (100 mM, pH 8.0),
MES buffer (50 mM, 6.0), MgCl2 (10 mM), NADP
+ (1 mM),
ATP (1 mM), hexokinase from S. cerevisiae (0.75 U; Sigma-
Aldrich, H4502-1KU), E. coli phosphomannose isomerase
(0.75 U; Megazyme, E-PMIEC), phosphoglucose isomerase
from baker’s yeast (0.75 U; Sigma-Aldrich, P5381-1KU),
and glucose-6-phosphate dehydrogenase from L. mesen-
teroides (0.75 U; Sigma-Aldrich, G9404-1KU). The absor-
bance of the NADPH formed was monitored by a
microplate reader (Synergy HT; BioTek8 ) at 340 nm in a 10-
min interval, and the maximum reading was recorded and
compared to the mannose standard curve.
To use RNase B as the substrate, the effective percentage
of a1–2-mannose-containing RNase B (44%) was deter-
mined by complete releasing of a1–2-linked mannose from
RNase B (0.8 mM) by incubating with EfMan-I (2.5 µM) at
37 °C for 4 h followed by quantification of the released
mannose using coupled enzyme assay as described above.
Kinetic studies using RNase B as the EfMan-I substrate
were carried out at 37 °C for 10 min in a total volume of
50 µL in duplicate in the presence of MES buffer (100 mM,
pH 6.0), EfMan-I (0.031 µM), and varied concentrations
(0.1, 0.2, 0.3, 0.5, 1.0, and 2.5 mM) of RNase B. Reactions
were quenched by incubating the reaction mixture at 98 °C
for 10 min. Precipitates were removed by centrifugation
(11 000 g, 5 min, 4 °C). The concentrations of mannose
released were determined similarly as described above using
the coupled enzyme assay [21].
1H NMR-based time course studies of EfMan-I
using ManapNP as the substrate
The assay was carried out in an NMR tube in 80% D2O/
H2O solution (0.6 mL) containing phosphate buffer
(10 mM, pH 6.0), ManapNP (10 mM), CaCl2 (4 mM), and
EfMan-I (0.75 mg). NMR spectra (16 scans for each time
point) were recorded at different reaction time points (0, 5,
10, 20, 30, 40, 50, 60, 90, and 120 min) in an 800 MHz
Bruker Avance III spectrometer at a temperature of 310 K.
The H2O signal at 4.705 p.p.m. was suppressed.
MALDI-TOF MS analysis of N-glycans released
from RNase B with or without EfMan-I treatment
RNase B or EfMan-I-treated RNase B (1 mg each) sample
was denatured by adding 0.5% SDS and DTT (40 mM).
The mixtures were incubated at 98 °C for 10 min and then
at room temperature for 5 min. The glycans were released
using 6 µg of peptide N-glycosidase F (PNGase F) by incu-
bating the reaction mixtures at 37 °C for 24 h. The degly-
cosylated proteins were precipitated by adding threefold
volume of cold ethanol and chilling the mixtures at "80 °C
for 2 h. The mixtures were then centrifuged at 15 0
00 r.p.m. 9for 20 min, and the supernatants containing the
glycans were dried in speed vacuum for matrix-assisted
laser desorption/ionization-time of flight (MALDI-TOF)
mass spectrometry (MS) analysis.
High-performance liquid chromatography (HPLC)
and MALDI-TOF MS analyses of 2-
aminobenzamide (2-AB)-labeled N-glycans
released from RNase B with or without EfMan-I
treatment
2-aminobenzamide solution (A) was prepared by adding
88 mg of 2-AB to 1 mL of DMSO/AcOH (7 : 3 by vol-
ume). The solution was stored at "20 °C. Sodium
cyanoborohydride solution (B) was freshly prepared by
adding 64 mg of NaCNBH3 to 1 mL of a solution mixture
of DMSO/AcOH (7 : 3 by volume). To a dried free reduc-
ing glycan sample (0.01–1 mg), solution A (5–50 µL) and
an equal volume of solution B were added. The mixture
was heated at 65 °C for 2 h. A 10-fold volume of acetoni-
trile was then added to precipitate the glycan-2AB conju-
gates. The mixture was cooled down at "20 °C for 1 h and
centrifuged at 13 000 r.p.m. 10for 2 min. The precipitate was
collected and dissolved in H2O (100–1000 µL). The
obtained mixture was centrifuged at 13 000 r.p.m. for
2 min. The supernatant was collected and diluted, and the
glycan-2AB conjugates were analyzed using HPLC with an
AdvanceBio Glycan Map column (Agilent 11) using a slow
gradient of Solvent A (ammonium formate, 100 mM, pH
4.5) and Solvent B (acetonitrile) and monitoring at A254 nm.
Crystallization of EfMan-I
EfMan-I in Tris/HCl buffer (10 mM, pH 7.5) was concen-
trated to 10 mg!mL"1 using centrifugal filter units (EMD
Millipore, Billerica, MA, USA) and crystallized by sitting
drop vapor diffusion in a 1 : 1 ratio of protein and reservoir
solution at 21 °C. The reservoir solution contained NaOAc
(0.1 M, pH 4.5) and NaH2PO4 (0.8 M)/K2HPO4 (1.2 M). The
crystals were briefly soaked in the reservoir solution that also
contained 30% glycerol prior to flash cooling in liquid nitro-
gen for X-ray diffraction data collection.
Data collection, model building, and refinement
X-Ray diffraction data were collected at Stanford Syn-
chrotron Radiation Lightsource (SSRL) beamline 12–2 at
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100 K. Diffraction data were indexed and integrated with
XDS [35], and then scaled with XSCALE [36]. A complete
diffraction data set was collected to 2.15 "A resolution with
an Rmerge of 9.6%. Data collection and structure refine-
ment statistics are given in Table S1. The crystals belong
to the orthorhombic space group C2221 with unit cell
parameters: a = 163.35 "A, b = 169.00 "A, c = 258.52 "A,
a = b = c = 90°, which contain four monomers per asym-
metric unit (VM = 2.70 "A
3/Da, solvent = 54.48%) [37].
The EfMan-I structure was solved by molecular replace-
ment applying a model of the previously solved a-man-
nosidase structure from S. pneumoniae (PDBID: 5swi)
using the program PHASER [38]. Atomic model building
was carried out with the molecular graphics program
COOT [39,40]. The structure was refined with the pro-
gram REFMAC5 [41] part of the CCP4 package [42].
Noncrystallographic symmetry restraints were included
during refinement. The final R-factor (15.5%) and R-free
(18.9%) along with the quality of the models are listed in
Table S1.
Results and Discussions
Cloning and purification of EfMan-I
The full-length gene of EF2217 (2142 bp encoding 713
aa) was cloned from the genomic DNA of E. faecalis
V583 into pET22b(+) vector. EfMan-I was expressed
as a C-His6-tagged fusion protein. Protein sequence
alignment (Fig. S1 and Table S2) showed that EfMan-
I shared 46.4% identity with SpGH92 from S. pneu-
moniae TIGR4 [22]. It also shared 34.1% and 32.1%
identities, respectively, with Bt2199 and Bt3990, which
are two a1–2-mannosidases from B. thetaiotaomicron
VPI-5482 [21].
EfMan-I was expressed at 20 °C as a soluble form
in E. coli BL21 (DE3) cells by induction using
0.15 mM of IPTG. Under these expression conditions,
85 mg of purified protein was routinely obtained from
1 L of E. coli cell culture by one-step nickel-nitrilotri-
acetic acid (Ni2+-NTA) affinity chromatography. This
expression level was comparable or higher than that
reported for Bt2199 and Bt3990 (> 500 nM or 41 mg
per liter culture) [21].
SDS/PAGE analysis (Fig. 1) indicated that the
apparent molecular weight of purified EfMan-I was
about 73 kDa, which was smaller than the calculated
molecular weight (82.7 kDa). Nevertheless, N-terminal
amino acid sequencing (Table S3) showed an intact N
terminus. The efficient one-step Ni2+-NTA affinity
chromatography process indicated the presence of the
C-His6-tag in the recombinant EfMan-I introduced by
cloning.
Substrate specificity studies of EfMan-I
Substrate specificity studies of EfMan-I (Fig. 2) in MES
buffer (100 mM, pH 6.0) using para-nitrophenyl-a-D-
mannopyranoside (ManapNP), a2-mannobiose, a3-
mannobiose, a6-mannobiose, D-mannotriose (Man3), or
3a,6a-mannopentaose (Man5) as the substrate showed
that a2-mannobiose was completely hydrolyzed by
EfMan-I, while ManapNP was partially hydrolyzed and
other compounds tested were not hydrolyzed by
EfMan-I in a 30-min time frame. However, after a pro-
longed incubation time of 24 h, ManapNP was com-
pletely hydrolyzed to form mannose and pNP (Fig. 2,
lane 2). It was interesting to note that both a3-manno-
biose and a6-mannobiose were also partially hydrolyzed
by EfMan-I to form mannose (Fig. 2, lanes 6 and 8) and
the hydrolytic activity of EfMan-I toward a3-manno-
biose was slightly higher than that toward a6-manno-
biose. Nevertheless, oligomannoses Man3 and Man5
were not suitable substrates for EfMan-I and they
remained intact even after a long (18 h) incubation per-
iod with 10-fold more enzyme (10 µg) at room tempera-
ture or at 37 °C (Fig. 2C). This suggested that EfMan-I
only catalyzed unbranched a1–3- and a1–6-linked man-
nose with low efficiency. The weak activity on cleaving
a1–6-linked mannose on an unbranched mannoside
chain is similar to a reported soil bacterium Soli-
talea canadensisa-mannosidase (Sca6Man4191) [43].
Therefore, EfMan-I is an a-mannosidase with high
efficiency in catalyzing the cleavage of a1–2-linked
mannose and with weak activity toward unbranched
a1–3- and a1–6-linked mannosides.
pH Profile and metal ion effects on EfMan-I
As shown in Fig. 3A, EfMan-I preferred a mild acidic
reaction condition and its optimum activity was
Fig. 1. SDS/PAGE (10% Tris-Glycine gel) analysis for the
expression and the purification of EfMan-I. Lanes: BI, whole-cell
extract before induction; AI, whole-cell extract after induction; L,
lysate after induction; PP, Ni2+-NTA column purified protein; M,
protein markers (Bio-Rad precision Plus Protein Standards, 10–
250 kDa).
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observed at pH 6.0. Medium activity was observed at
pH 6.5 and in a pH range of 5.0–5.5. EfMan-I activity
decreased drastically when the pH was at or below 4.5,
or at or above 7.0. The effects of a metal ion such as
Ca2+ or Mg2+ and a chelating agent EDTA on the
activity of EfMan-I in catalyzing the cleavage of Man-
apNP were examined at pH 6.0. As shown in Fig. 3B,
the activity of EfMan-I was abolished by the addition
of EDTA, while it was not significantly affected by the
addition of Ca2+ or Mg2+ for up to 20 mM, indicating
that a pre-existing metal ion bond to EfMan-I was
important for its catalytic activity.
Kinetic studies of EfMan-I
Three substrates including ManapNP, a2-mannobiose,
and RNaseB were used to determine the apparent kinet-
ics data for EfMan-I. As shown in Table 1, ManapNP
was the least efficient substrate among the three. Using
ManapNP as the substrate, the catalytic efficiency (kcat/
KM) of EfMan-I was 4.7 9 10
-2 s"1!mM"1 or
2.82 min"1!mM"1 (Fig. S2). In comparison, the catalytic
efficiencies of Bt2199 and Bt3990 were 0.84 and
1.3 min"1!mM"1, respectively [21]. EfMan-I was the
most efficient in catalyzing the cleavage of a1–2-manno-
syl linkage in a2-mannobiose with a catalytic efficient
(kcat/KM) of 58 s
"1 mM"1 (Fig. S3), which was more
than 1200-fold higher than that of ManapNP. The dif-
ference was contributed by both a higher turnover num-
ber (367-folder) and an improved binding (3.5-fold) for
a2-mannobiose. RNase B was also an efficient substrate
with a catalytic efficient (kcat/KM) of 22 s
"1!mM"1
(Fig. S4), which was about 468-fold higher than that of
ManapNP.
1H NMR-based time course studies of EfMan-I
using ManapNP as the substrate
1H NMR-based time course studies (Fig. S5) showed
that EfMan-I-catalyzed reaction follows an inversion
mechanism similar to that described for Bt2199 and
Bt3990 previously [21]. For example, b-mannose was
observed as the main product of EfMan-I from Man-
apNP substrate in the first 10 min. With a longer reac-
tion time and the accumulation of b-mannose product,
a-mannose appeared quickly due to a quick mutarota-
tion process.
MALDI-TOF MS analysis of N-glycans released
from RNase B with or without EfMan-I treatment
In order to test the activity of EfMan-I in catalyzing the
cleavage of a1–2-mannose from high-mannose N-gly-
cans on glycoprotein substrates, RNase B, a glycopro-
tein containing a single N-glycosylation, was treated
with EfMan-I. The N-glycans of RNase B with or with-
out EfMan-I-treatment were then released by PNGase
F [44,45] and analyzed by MALDI-TOF MS [46]. As
shown in Fig. S6, without EfMan-I-treatment (RNase B
control), Man5GlcNAc2, Man6GlcNAc2, Man7GlcN
Ac2, Man8GlcNAc2, and Man9GlcNAc2 were observed
as the N-glycans released from RNase B by PNGase F
(Fig. S6A). In comparison, with EfMan-I treatment, all
Man6–9GlcNAc2 N-glycan structures were converted to
Man5GlcNAc2 (Fig. S6B). These results confirmed that
EfMan-I was specific for catalyzing the cleavage of a1–
2-linked mannose residues on high-mannose-type N-gly-
cans on glycoproteins.
A B C
Fig. 2. Substrate specificity studies of EfMan-I by TLC analysis with reactions carried out at 37 °C for (A) 30 min or (B) 24 h in the
presence of EfMan-I (1.0 µg) (developing solvent used was n-PrOH : H2O : NH3!H2O = 5 : 2 : 1, by volume). For (C), reactions were
carried out in the presence of EfMan-I (10 µg) at room temperature (for 10a and 12a) or at 37 °C (for 10b and 12b) for 18 h (developing
solvent used was n-PrOH:H2O:NH3!H2O = 3 : 2 : 1, by volume). Lanes: 1, mannose; 2, ManapNP in the presence of EfMan-I; 3, ManapNP;
4, a2-mannobiose in the presence of EfMan-I; 5, a2-mannobiose; 6, a3-mannobiose in the presence of EfMan-I; 7, a3-mannobiose; 8, a6-
mannobiose in the presence of EfMan-I; 9, a6-mannobiose; 10, Man3 in the presence of EfMan-I; 11, Man3; 12, Man5 in the presence of
EfMan-I; 13, Man5.
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HPLC and MALDI-TOF MS analyses of 2-AB-
labeled N-glycans released from RNase B with or
without EfMan-I treatment
To quantitatively analyze the activity of EfMan-I
against glycoprotein, the N-glycans of RNase B with or
without EfMan-I treatment were released and labeled
with 2-AB [47]. As shown in Figs 4 and Fig. S7, without
EfMan-I treatment, 2-AB-labeled Man5GlcNAc2
(~ 50%), Man6GlcNAc2 (~ 37%), and Man7–9GlcNAc2
(~ 13%) were observed for the RNase B sample. With
EfMan-I treatment, all Man6–9GlcNAc2 on RNase B
were converted to Man5GlcNAc2.
Crystal structure of EfMan-I
EfMan-I crystallized in Space group C2221 with four
molecules per asymmetric unit. However, given the
limited amount of surface area buried between mono-
mers in the crystal packing, EfMan-I is most likely
monomeric in solution. The electron density, at 2.15 "A
resolution, clearly defined residues 1–712 in all four
subunits in the asymmetric unit. The overall structure
of EfMan-I contains two domains; an N-terminal 14-
stranded antiparallel b-sandwich domain and a larger
C-terminal helical domain with (a/a)6 topology
(Fig. 5A). This two-domain architecture is seen in
homologous GH92 a-mannosidases [21,22,49] and
other glycosidases [23,50–52]. The N-terminal b-sand-
wich displays some similarities to non-catalytic b-sand-
wich domains found in larger GH38 family
glycosidases like Drosophila Golgi retaining a-man-
nosidases [53] and bovine lysosomal a-mannosidase
[54]. In EfMan-I and in homologous GH92 family
a-mannosidases, the active site lies in a cleft between
the N-terminal b-sandwich domain and the C-terminal
(a/a)6 domain. It is interesting to note that the two-do-
main glycosidases are typically exo-glycosidases, while
glycosidases with only a single (a/a)6 domain are typi-
cally endo-glycosidases [55,56], suggesting the b-sand-
wich domain restricts the active site to only terminal
sugars.
The active site is located close to the center of the
(a/a)6 domain, and the N-terminal b-sandwich domain
helps to shape part of the active site. Specifically,
Trp68 of the N-terminal domain lies above the active
site and helps in binding substrate and substrate ana-
logs as observed in other a-mannosidases [21,22]. Elec-
tron density clearly reveals that the active site of all
four subunits in the asymmetric unit contains a bound
metal with an octahedral coordination geometry.
Although no divalent cations were included in protein
purification or crystallization, the metal was modeled
as a calcium ion because other GH92 family a-man-
nosidases require calcium for activity and calcium ions
were observed in their structures [21,22,49]. The pres-
ence of a calcium ion in the crystal structure can
explain the activity of EfMan-I observed without the
addition of an external metal cation. The calcium is
Fig. 3. pH Profile (A) as well as metal ion and EDTA effects (B) on EfMan-I using ManapNP as the substrate. For A, buffers used were as
follows: citric acid-Na2HPO4, pH 3.0–4.0; NaOAc/HOAc, pH 4.5; MES, pH 5.0–6.5, and Tris/HCl pH 7.0–9.0. For B, Black columns, MgCl2;
white columns, CaCl2; light gray columns, EDTA; dark gray column, no metal and no EDTA control.
Table 1. Apparent kinetics data of EfMan-I.
Acceptor kcat (s
"1) KM (mM)
kcat/KM
(s"1! mM "1)
ManapNP 0.49 # 0.03 11 # 1.7 4.7 9 10"2
a2-mannobiose (1.8 # 0.1) 9 102 3.1 # 0.3 58
RNase B 42 # 3 1.9 # 0.2 22
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coordinated by the side chains of Asn562 (2.6 "A),
Gln563 (2.4 "A), and Asp604 (2.4 "A) together with two
water molecules (2.6 and 2.7 "A) (Fig. 5B). The sixth
ligand comes from a ‘tube’ of electron density, which
was modeled as glycerol since it was added as a cry-
oprotectant. Additionally, electron density was
observed near the calcium ion in the active site in all
four monomers in the crystallographic asymmetric
unit, which was also modeled as glycerol (Fig. 5B).
Glycerol was also observed in the active site of other
a-mannosidases (see below) [21–23].
Strong electron density was also observed adjacent to
Asn20 that was modeled as a potassium ion since it was
present in the crystallization conditions (Fig. 5C). Place-
ment of sodium, also present in the crystallization con-
ditions, resulted in strong positive difference electron
density after subsequent rounds of refinement, confirm-
ing the likelihood of a more electron dense potassium
ion at this location. Ligation distances and geometry are
also similar to potassium ions in other protein structures
[57]. The potassium ion binds on the surface of the pro-
tein at the interface between the N-terminal and C-ter-
minal domains, where Asn20 Od1 coordinates (2.7 "A)
together with carbonyl oxygens from Thr597 (2.8 "A)
and Tyr599 (2.7 "A) (Fig. 5C). Two water molecules fin-
ish the coordination sphere resulting in a square pyrami-
dal geometry. Although this potassium ion is also
observed in all four monomers of the asymmetric unit, it
is likely not directly involved in catalysis because it
binds on the peripheral of the protein over 13 "A from
the active site. However, the presence of a potassium ion
situated at the interface between the two domains
suggests the ion may play a role in helping position the
proper orientation between the domains to shape the
active site. This hypothesis still remains to be tested in
future studies. In comparison, a sodium ion was mod-
eled in a similar position in the B. thetaiotaomicron a-
mannosidase Bt2199 (PDBID 2ww2) [21]. In Bt2199
structure, the ion is octahedrally coordinated by main
chain carbonyl oxygens of Ser40, Tyr643, Gly645, and
Asp648 with two waters completing the octahedral
coordination.
Comparison of EfMan-I structure to other
a-mannosidases
The closest EfMan-I homolog with a known structure is
an a-mannosidase from human pathogen S. pneumoniae
(SpGH92) [22], which has 47% sequence identity. The
two crystal structures superimpose with an rmsd of
1.07 "A over 672 equivalent a-carbons (Fig. 6A). The
only major deviation is in a loop centered around resi-
due Met359 near the active site (Fig. 6A). In the
EfMan-I structure, the loop adopts a conformation that
closes in on the active site. However, in the SpGH92
structure, one of the four monomers in the asymmetric
unit adopts two conformations of the loop, one resem-
bles more closely the conformation of EfMan-I. The
three other SpGH92 monomers in the asymmetric unit
only adopt one conformation extending away from the
active site as observed in Fig. 6A. The different confor-
mations between these two structures that help shape
the active-site pocket may be important in substrate
binding specificity. However, the corresponding loop in
Fig. 4. HPLC analysis of 2-AB-labeled high-mannose N-linked glycans from RNase B without (A) and with (B) EfMan-I treatment; and
schematic illustration of the reaction catalyzed by EfMan-I (C) [48].12
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the a-mannosidases from B. thetaiotaomicron (the next
closest homolog at 32–34% identity) displays (not
shown) this loop in a closed conformation similar to
EfMan-I [21,49].
The active sites of the EfMan-I and SpGH92 struc-
tures are very similar with homologous residues coordi-
nating the calcium ion (Fig. 6B). In the EfMan-I
structure, two glycerol molecules are observed in the
active site, one is involved in coordinating the calcium
ion ("1 subsite), and another glycerol stacks up against
Trp68 (+1 subsite). In the SpGH92 structure (PDBID
5swi), crystals were soaked with a1–2-mannobiose,
which was hydrolyzed and only mannose was observed
to bind to the +1 subsite location in a similar location
to the secondary glycerol of EfMan-I (Fig. 6B). The "1
subsite of SpGH92 was occupied by a glycerol molecule
that coordinated the calcium ion as also observed in
EfMan-I. Previous a-mannosidase kinetic and struc-
tural analyses have proposed a general acid–base mech-
anism and identified catalytic residues [21]. These
residues map to Glu494 and Asp604 in serving as the
respective general acid and general base catalytic resi-
dues in EfMan-I (Fig. 6B). It is interesting to note that
Asp604 also serves as a calcium ligand in the active
site.
Several crystal structures have been determined for
GH92 family a-mannosidases from the human gut
microbe B. thetaiotaomicron (Bt) with various sub-
strates and inhibitors bound in the active site [21,49].
These include Bt2119, Bt3990, Bt3130, and Bt3965, all
of which have similar structures to EfMan-I. Bt3990,
which has a 32% sequence identity to EfMan-I, super-
imposes onto EfMan-I with an rmsd of 1.29 "A over
696 equivalent a-carbons. The structure of Bt3990 was
determined with a nonhydrolyzable disaccharide of
thio-a2-mannobioside (PDBID 2ww3). Superposition
of this active site onto EfMan-I is shown in Fig. 7,
which reveals they are very similar. The glycerol in
EfMan-I that coordinates the calcium ion superim-
poses more on the –1 subsite saccharide, while the sec-
ond glycerol occupies a position in between the two
saccharides of the thio-a2-mannobioside substrate ana-
log in Bt3990. The only main difference in the active
sites is the movement of Asn601 in Bt3990. The equiv-
alent residue (Asn562) of EfMan-I coordinates the cal-
cium ion, while in Bt3990, it shifts down and a water
Fig. 5. Overall structure of EfMan-I
monomer (A), its active site (B), and
potassium-binding site (C). Ribbon drawing
of EfMan-I colored by a rainbow gradient
according to sequence number, starting
with blue at the N terminus, and ending
with red at the C terminus. The active site
is identified by the Ca2+ ion shown as a
green sphere together with glycerol
molecules (sticks) that interact with the
Ca2+ ion shown as a green sphere
together with the coordination ligands
(water molecule ligands shown as smaller
red spheres). Yellow dashed lines
represent coordination interactions
(between 2.6–2.9 "A). The two glycerol
molecules modeled in the active site are
shown as sticks with white-colored carbon
atoms. A K+ ion binds to the peripheral of
the (a/a)6 domain is shown as a purple-
colored sphere together with the
coordination ligands (water molecule
ligands shown as smaller red spheres).
Only main chain atoms are shown for
Thr597 and Tyr599.
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molecule occupies the vacated coordination space.
However, in another Bt3990 structure complexed with
the inhibitor swainsonine (PDBID 2ww0), Asn601
does indeed coordinate the calcium ion similar to
Asn562 of EfMan-I.
In conclusion, a new a1–2-mannosidase from E. fae-
calis (EfMan-I) has been identified and characterized.
It has been found to catalyze the cleavage of a1–2-
linked mannose residues highly efficiently from not
only oligomannosides but also glycoproteins contain-
ing high-mannose-type N-glycans using ribonuclease B
as a model glycoprotein. It is an inverting glycosidase
similar to two characterized GH92 a1–2-mannosidases
(Bt3990 and Bt2199) from B. thetaiotaomicron VPI-
5482. The crystal structure of EfMan-I reveals a simi-
lar fold to other GH92 a-mannosidases and identifies
residues in the active site that ligate the essential cal-
cium ion and are involved in substrate binding and
catalysis. Ordered glycerol molecules, used for cry-
oprotection, bind in the active site with one molecule
ligating to the active-site calcium ion. An unexpected
potassium ion was observed bridging two domains
near the active site. With a good expression level in
E. coli, high activity and high selectivity on cleaving
a1–2-linked mannose residues in oligomannose struc-
tures including those attached to glycoproteins, the
newly characterized EfMan-I is a powerful tool for
in vitro enzymatic modification of high-mannose-type
N-glycans on glycoproteins. Its characterization is also
helpful for better understanding the use of host or
dietary glycoproteins as nutrients by E. faecalis, a
Gram-positive commensal bacterium and an oppor-
tunistic pathogen that can cause health care-associated
infection (HAI).
Fig. 6. Superposition of EfMan-I (salmon color) and SpGH92 (slate blue) structures (A) and their active sites (B). They superimpose with an
rmsd of 1.07 "A over 672 equivalent a-carbons. Calcium ions in the active site are shown as green spheres, and the 359 loop near the active
site is highlighted in bright red color for EfMan-I. The side chains of residues that coordinate the calcium ion are shown along with ordered
glycerol molecules found in both mannosidase structures. Note that in each structure a glycerol coordinates the calcium ion and in the
EfMan-I structure, another glycerol binds in a similar location to mannose observed in SpGH92, which is 3.4 "A below the indole ring of
Trp68. Glu494 and Asp604 are proposed to be the respective general acid and general base in catalysis.
Fig. 7. Superposition of EfMan-I (salmon color) and Bt3990 (green)
active sites. The side chains of residues that coordinate the
calcium ion are shown along with ordered glycerol molecules
found in EfMan-I structure (pink-colored carbon atoms) and the
substrate analog thio-a2-mannobioside in Bt3990 (pale-green
carbon atoms). Location of the calcium ion is shown by spheres
with colors corresponding to their respective active sites.
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